Literature DB >> 30150420

From Mouse Models to Human Disease: An Approach for Amyotrophic Lateral Sclerosis.

Aziza Rashed Alrafiah1.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal adult-onset neurodegenerative disorder. There are several genetic mutations that lead to ALS development, such as chromosome 9 hexanucleotide repeat 72 (C9ORF72), transactive response DNA-binding protein (TARDBP), superoxide dismutase 1 (SOD1) and fused in sarcoma (FUS). ALS is associated with disrupted gene homeostasis causing aberrant RNA processing or toxic pathology. Several animal models of ALS disease have been developed to understand whether TARDBP-mediated neurodegeneration results from a gain or a loss of function of the protein, however, none exactly mimic the pathophysiology and the phenotype of human ALS. Here, the pathophysiology of specific ALS-linked gene mutations is discussed. Furthermore, some of the generated mouse models, as well as the similarities and differences between these models, are comprehensively reviewed. Further refinement of mouse models will likely aid the development of a better form of model that mimics human ALS. However, disrupted gene homeostasis that causes mutation can result in an ALS-like syndrome, increasing concerns about whether neurodegeneration and other effects in these models are due to the mutation or to gene overexpression. Research on the pleiotropic role of different proteins present in motor neurons is also summarized. The development of better mouse models that closely mimic human ALS will help identify potential therapeutic targets for this disease. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; C9ORF72; FUS; SOD1; TARDBP; motor neuron diseases; mouse models; review

Mesh:

Substances:

Year:  2018        PMID: 30150420      PMCID: PMC6199613          DOI: 10.21873/invivo.11339

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  125 in total

1.  Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration.

Authors:  Clotilde Lagier-Tourenne; Michael Baughn; Frank Rigo; Shuying Sun; Patrick Liu; Hai-Ri Li; Jie Jiang; Andrew T Watt; Seung Chun; Melanie Katz; Jinsong Qiu; Ying Sun; Shuo-Chien Ling; Qiang Zhu; Magdalini Polymenidou; Kevin Drenner; Jonathan W Artates; Melissa McAlonis-Downes; Sebastian Markmiller; Kasey R Hutt; Donald P Pizzo; Janet Cady; Matthew B Harms; Robert H Baloh; Scott R Vandenberg; Gene W Yeo; Xiang-Dong Fu; C Frank Bennett; Don W Cleveland; John Ravits
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-29       Impact factor: 11.205

2.  ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects.

Authors:  Haiyan Qiu; Sebum Lee; Yulei Shang; Wen-Yuan Wang; Kin Fai Au; Sherry Kamiya; Sami J Barmada; Steven Finkbeiner; Hansen Lui; Caitlin E Carlton; Amy A Tang; Michael C Oldham; Hejia Wang; James Shorter; Anthony J Filiano; Erik D Roberson; Warren G Tourtellotte; Bin Chen; Li-Huei Tsai; Eric J Huang
Journal:  J Clin Invest       Date:  2014-02-10       Impact factor: 14.808

Review 3.  TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies.

Authors:  Todd J Cohen; Virginia M Y Lee; John Q Trojanowski
Journal:  Trends Mol Med       Date:  2011-07-23       Impact factor: 11.951

4.  Entorhinal cortical neurons are the primary targets of FUS mislocalization and ubiquitin aggregation in FUS transgenic rats.

Authors:  Cao Huang; Jianbin Tong; Fangfang Bi; Qinxue Wu; Bo Huang; Hongxia Zhou; Xu-Gang Xia
Journal:  Hum Mol Genet       Date:  2012-07-23       Impact factor: 6.150

5.  C9orf72 BAC Mouse Model with Motor Deficits and Neurodegenerative Features of ALS/FTD.

Authors:  Yuanjing Liu; Amrutha Pattamatta; Tao Zu; Tammy Reid; Olgert Bardhi; David R Borchelt; Anthony T Yachnis; Laura P W Ranum
Journal:  Neuron       Date:  2016-04-21       Impact factor: 17.173

6.  HO-1 induction in motor cortex and intestinal dysfunction in TDP-43 A315T transgenic mice.

Authors:  Yansu Guo; Qian Wang; Kunxi Zhang; Ting An; Pengxiao Shi; Zhongyao Li; Weisong Duan; Chunyan Li
Journal:  Brain Res       Date:  2012-04-12       Impact factor: 3.252

Review 7.  Disease animal models of TDP-43 proteinopathy and their pre-clinical applications.

Authors:  Yu-Chih Liu; Po-Min Chiang; Kuen-Jer Tsai
Journal:  Int J Mol Sci       Date:  2013-10-09       Impact factor: 5.923

8.  ALS-causative mutations in FUS/TLS confer gain and loss of function by altered association with SMN and U1-snRNP.

Authors:  Shuying Sun; Shuo-Chien Ling; Jinsong Qiu; Claudio P Albuquerque; Yu Zhou; Seiya Tokunaga; Hairi Li; Haiyan Qiu; Anh Bui; Gene W Yeo; Eric J Huang; Kevin Eggan; Huilin Zhou; Xiang-Dong Fu; Clotilde Lagier-Tourenne; Don W Cleveland
Journal:  Nat Commun       Date:  2015-01-27       Impact factor: 14.919

Review 9.  Pathogenesis of FUS-associated ALS and FTD: insights from rodent models.

Authors:  Matthew Nolan; Kevin Talbot; Olaf Ansorge
Journal:  Acta Neuropathol Commun       Date:  2016-09-06       Impact factor: 7.801

10.  Impairment of mitochondrial calcium handling in a mtSOD1 cell culture model of motoneuron disease.

Authors:  Manoj Kumar Jaiswal; Wolf-Dieter Zech; Miriam Goos; Christine Leutbecher; Alberto Ferri; Annette Zippelius; Maria Teresa Carrì; Roland Nau; Bernhard U Keller
Journal:  BMC Neurosci       Date:  2009-06-22       Impact factor: 3.288

View more
  6 in total

1.  Assessing neuraxial microstructural changes in a transgenic mouse model of early stage Amyotrophic Lateral Sclerosis by ultra-high field MRI and diffusion tensor metrics.

Authors:  Rodolfo G Gatto; Carina Weissmann; Manish Amin; Ariel Finkielsztein; Ronen Sumagin; Thomas H Mareci; Osvaldo D Uchitel; Richard L Magin
Journal:  Animal Model Exp Med       Date:  2020-04-16

2.  Suppression of Conditional TDP-43 Transgene Expression Differentially Affects Early Cognitive and Social Phenotypes in TDP-43 Mice.

Authors:  Pablo R Silva; Gabriela V Nieva; Lionel M Igaz
Journal:  Front Genet       Date:  2019-04-24       Impact factor: 4.599

3.  ALS blood expression profiling identifies new biomarkers, patient subgroups, and evidence for neutrophilia and hypoxia.

Authors:  William R Swindell; Colin P S Kruse; Edward O List; Darlene E Berryman; John J Kopchick
Journal:  J Transl Med       Date:  2019-05-22       Impact factor: 5.531

4.  Neuronal over-expression of Oxr1 is protective against ALS-associated mutant TDP-43 mislocalisation in motor neurons and neuromuscular defects in vivo.

Authors:  Matthew G Williamson; Mattéa J Finelli; James N Sleigh; Amy Reddington; David Gordon; Kevin Talbot; Kay E Davies; Peter L Oliver
Journal:  Hum Mol Genet       Date:  2019-11-01       Impact factor: 6.150

5.  Overexpression of miR-124 in Motor Neurons Plays a Key Role in ALS Pathological Processes.

Authors:  Ana Rita Vaz; Daniela Vizinha; Hermes Morais; Ana Rita Colaço; Gecioni Loch-Neckel; Marta Barbosa; Dora Brites
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

Review 6.  Defining novel functions for cerebrospinal fluid in ALS pathophysiology.

Authors:  Koy Chong Ng Kee Kwong; Arpan R Mehta; Maiken Nedergaard; Siddharthan Chandran
Journal:  Acta Neuropathol Commun       Date:  2020-08-20       Impact factor: 7.801

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.